European Biotech (NASDAQ:EBAC) announced in an 8-K this morning that it has increased its PIPE by $7.8 million and added $7 million to the convertible loans attached to the combination with biotech firm Oculis.
The new PIPE cash comes at $10 per share and joins $63.3 million in existing PIPE financing for a total of 7,118,891 PIPE shares, adding about $71.2 million to the deal. The expansion of the convertible loan agreement takes the facility to $19.67 million, with the lenders set to convert their rights into shares at $10 per share.
Together with a non-redemption agreement ensuring 700,789 shares will not be redeemed, European Biotech has now secured about $97.85 million in committed financing for the deal. This is just below the transaction’s $100 million minimum cash condition, but its public share capital would still bridge the gap provided redemptions were below about 98.4%.
The parties announced their $218 million combination in October 2022. Lausanne, Switzerland-based Oculis is developing a range of therapies for eye diseases with the most advanced having entered Phase III trials.
Earlier this month, it announced it has completed stage one of its enrollment for this Phase III trial, studying he effectiveness of OCS-01, which has the potential to be the the first topical eye drop and non-invasive treatment for Diabetic Macular edema.
two (NYSE:PIAI) announced in an 8-K this morning that it has pushed back its special meeting one week from March 24 to 10 am ET, March 31. Shareholders at the meeting will consider a proposal to extend its transaction deadline from April 1 to January 1, 2024. The SPAC’s sponsor has not yet offered to...
Terms Tracker for the Week Ending March 17, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Despite this week’s headlines about bank failures, EF Hutton managed to file both a new S-1 registration statement and price an IPO. They should have...
Latest SPAC Liquidations: Northern Genesis III, MSD, and Tech and Energy Transition Corp. Northern Genesis Acquisition Corp. III (NGC) to Liquidate on March 24 Northern Genesis III (NYSE:NGC) announced that it will redeem all outstanding shares effective as of the close of business on March 27. Shares will cease trading on March 24 and the per-share...
Tech and Energy Transition Corp. (NASDAQ: TETC) announced this afternoon that its shareholders have voted against a proposal to extend the SPAC’s timeline to complete a business combination. Holders of 38,069,946 shares of TETC’s common stock, comprised of 28,495,396 shares of Class A common stock, and 9,575,000 shares of Class B common stock, were present at...
Direct Selling Acquisition Corp. (NYSE: DSAQ) announced this morning that it intends to adjourn its extension vote, originally scheduled to be held on March 22, and will reconvene on March 24 at 11:00 a.m. The SPAC has also extended the redemption deadline to March 22 at 5:00 p.m. It is currently facing a completion deadline of March...